Rapport Therapeutics (RAPP) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, with legal counsel recording the minutes and confirmation that the meeting was held in accordance with bylaws and Delaware law.
Stockholders were welcomed, and the agenda was limited to official business as described in the notice and proxy statement.
Directors, executive team, and representatives from the audit firm and legal counsel were introduced.
Rules of conduct and voting eligibility were explained, with instructions for submitting questions and voting through the virtual platform.
Board and executive committee updates
Three nominees for Class 2 directors were presented for election to serve a three-year term, with no additional nominations received.
The board unanimously recommended voting in favor of the director nominees.
Corporate governance
An independent inspector of elections was appointed to oversee and tabulate voting results.
The audit committee, composed entirely of independent directors, appointed the audit firm for the coming fiscal year.
Stockholder ratification of the audit firm was sought as a matter of good governance, though not required by bylaws.
Latest events from Rapport Therapeutics
- Phase 2A epilepsy data for RAP-219 expected Q3 2024, with pipeline and cash runway through 2026.RAPP
TD Cowen 45th Annual Healthcare Conference9 Jul 2026 - 77.8% median seizure reduction and 24% seizure freedom achieved, supporting Phase 3 trials.RAPP
Study Result8 Jul 2026 - Lead program demonstrates robust efficacy in epilepsy, with phase 3 trials and expansion planned.RAPP
Stifel 2025 Healthcare Conference30 Jun 2026 - RAP-219's pivotal epilepsy and bipolar trials advance with robust funding and global reach.RAPP
Stifel 2026 Virtual CNS Forum15 Jun 2026 - Global phase III epilepsy trials advance with robust data and broad commercial potential.RAPP
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - RAP-219 shows strong efficacy in epilepsy, with phase III and LAI programs advancing.RAPP
Jefferies Global Healthcare Conference 20263 Jun 2026 - RAP-219 shows strong efficacy in drug-resistant epilepsy, advancing toward Phase 3 trials.RAPP
Corporate presentation7 May 2026 - RAP-219's 90% seizure reduction and $20M deal narrowed losses and extended cash runway into 2029.RAPP
Q1 20267 May 2026 - RAP-219 advances to global phase III after strong efficacy in focal seizures and a major China deal.RAPP
Leerink Global Healthcare Conference 20267 May 2026